Posted by Michael Wonder on 16 Jan 2024
Vertex announces US FDA approval of Casgevy (exagamglogene autotemcel) for the treatment of transfusion-dependent beta thalassaemia
16 January 2024 - Approximately 1,000 patients in the US 12 years of age and older are now eligible for this one time treatment.
Vertex Pharmaceuticals announced today that the US FDA has approved Casgevy (exagamglogene autotemcel), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassaemia in patients 12 years and older.
